1. Home
  2. NRIX vs KN Comparison

NRIX vs KN Comparison

Compare NRIX & KN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.88

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Knowles Corporation

KN

Knowles Corporation

N/A

Current Price

$28.39

Market Cap

2.0B

ML Signal

N/A

Company Overview

Basic Information
Metric
NRIX
KN
Founded
2009
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Electronics/Appliances
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
NRIX
KN
Price
$15.88
$28.39
Analyst Decision
Strong Buy
Buy
Analyst Count
13
3
Target Price
$29.46
$22.33
AVG Volume (30 Days)
844.9K
689.4K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
118.94
EPS
N/A
0.50
Revenue
$76,987,000.00
$593,200,000.00
Revenue This Year
N/A
$9.40
Revenue Next Year
$29.30
$6.98
P/E Ratio
N/A
$54.97
Revenue Growth
99.31
7.17
52 Week Low
$8.18
$12.19
52 Week High
$22.50
$27.73

Technical Indicators

Market Signals
Indicator
NRIX
KN
Relative Strength Index (RSI) 42.26 73.49
Support Level $15.62 $23.81
Resistance Level $19.98 N/A
Average True Range (ATR) 0.78 0.94
MACD -0.03 0.10
Stochastic Oscillator 36.46 98.68

Price Performance

Historical Comparison
NRIX
KN

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

Share on Social Networks: